Kite's Gene Therapy Yescarta Gets Biosimilar Treatment With Second-In-Class Approval

Much like it did for the first biosimilars, US FDA approved Yescarta without an advisory committee, as Novartis' first-in-class CAR-T cell therapy already set the stage for an agency review.